glp-1 obesity cardiovascular news The Big Trial of a drug (Wegovy) to Reduce Major Events How GLP-1 Medications Reduce Heart

Singh et al., 2019

It helps protect the skin from oxidative stress caused by factors such as UV exposure, pollution, and environmental damage

67 RaiA.TripathiP.DwivediS.DubeyS.ShriM.KumarS.et al (2011)

Key results at 80 weeks: Participants on the 4 mg dose lost an average of 47.2 lbs (19.0%) Participants on the 12 mg dose lost an average of 70.3 lbs (28.3%) 45.3% of participants on the 12 mg dose achieved at least 30% weight loss a level historically associated with bariatric surgery outcomes The 4 mg dose showed a lower rate of discontinuation due to adverse events than even placebo In a study extension to 104 weeks, participants with a starting BMI of 35 or higher who received 12 mg lost up to an average of 85.0 lbs (30.3%)

This page provides general information only and does not make specific medicinal, cosmetic, or therapeutic claims